UniQure PE Ratio 2013-2022 | QURE

Current and historical p/e ratio for UniQure (QURE) from 2013 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. UniQure PE ratio as of February 03, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

UniQure PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-03 22.52 0.00
2022-09-30 18.76 $-2.69 0.00
2022-06-30 18.64 $-2.46 0.00
2022-03-31 18.07 $6.89 2.62
2021-12-31 20.74 $6.98 2.97
2021-09-30 32.01 $6.80 4.71
2021-06-30 30.80 $6.38 4.83
2021-03-31 33.69 $-3.09 0.00
2020-12-31 36.13 $-2.81 0.00
2020-09-30 36.83 $-3.77 0.00
2020-06-30 45.06 $-3.14 0.00
2020-03-31 47.45 $-3.01 0.00
2019-12-31 71.66 $-3.12 0.00
2019-09-30 39.36 $-2.74 0.00
2019-06-30 78.15 $-2.75 0.00
2019-03-31 59.65 $-2.49 0.00
2018-12-31 28.82 $-2.34 0.00
2018-09-30 36.39 $-2.66 0.00
2018-06-30 37.80 $-2.47 0.00
2018-03-31 23.50 $-2.73 0.00
2017-12-31 19.59 $-2.94 0.00
2017-09-30 9.60 $-2.61 0.00
2017-06-30 6.19 $-2.81 0.00
2017-03-31 5.78 $-2.96 0.00
2016-12-31 5.60 $-3.08 0.00
2016-09-30 7.65 $-3.14 0.00
2016-06-30 7.37 $-3.74 0.00
2016-03-31 11.88 $-2.76 0.00
2015-12-31 16.54 $-2.47 0.00
2015-09-30 20.45 $-2.50 0.00
2014-12-31 14.81 $-2.01 0.00
2014-09-30 9.25 $-2.97 0.00
2014-06-30 13.59 $-3.09 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.054B $0.524B
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00